ADIL vs. AEZS, NRBO, VINC, INDP, LUMO, SNSE, IBIO, PPBT, SYBX, and VBIV
Should you be buying Adial Pharmaceuticals stock or one of its competitors? The main competitors of Adial Pharmaceuticals include Aeterna Zentaris (AEZS), NeuroBo Pharmaceuticals (NRBO), Vincerx Pharma (VINC), Indaptus Therapeutics (INDP), Lumos Pharma (LUMO), Sensei Biotherapeutics (SNSE), iBio (IBIO), Purple Biotech (PPBT), Synlogic (SYBX), and VBI Vaccines (VBIV). These companies are all part of the "pharmaceutical preparations" industry.
Aeterna Zentaris (NASDAQ:AEZS) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings, dividends and community ranking.
Aeterna Zentaris presently has a consensus price target of $60.00, suggesting a potential upside of 617.70%. Given Adial Pharmaceuticals' higher probable upside, equities analysts clearly believe Aeterna Zentaris is more favorable than Adial Pharmaceuticals.
Adial Pharmaceuticals has lower revenue, but higher earnings than Aeterna Zentaris.
Aeterna Zentaris has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, Adial Pharmaceuticals has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.
Adial Pharmaceuticals has a net margin of 0.00% compared to Adial Pharmaceuticals' net margin of -760.32%. Adial Pharmaceuticals' return on equity of -83.45% beat Aeterna Zentaris' return on equity.
Aeterna Zentaris received 311 more outperform votes than Adial Pharmaceuticals when rated by MarketBeat users. Likewise, 62.17% of users gave Aeterna Zentaris an outperform vote while only 58.06% of users gave Adial Pharmaceuticals an outperform vote.
In the previous week, Aeterna Zentaris had 3 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 6 mentions for Aeterna Zentaris and 3 mentions for Adial Pharmaceuticals. Aeterna Zentaris' average media sentiment score of 1.23 beat Adial Pharmaceuticals' score of 0.57 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media.
0.7% of Aeterna Zentaris shares are held by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are held by institutional investors. 0.1% of Aeterna Zentaris shares are held by insiders. Comparatively, 14.5% of Adial Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Aeterna Zentaris beats Adial Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
Get Adial Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adial Pharmaceuticals Competitors List
Related Companies and Tools
